Immunotherapy represented by PD-L1 and PD-1 blockade has undoubtedly become a breakthrough in cancer treatment, so we investigated whether the CAF-based signature could predict response to anti-PD-1 and anti-PD-L1 based on two immunotherapy cohorts. This evidence concerns the gene CD274 and cancer.